Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

There are conflicting data regarding the effects of TK inhibitors on tumor immunity ... The study of imatinib and sorafenib would be insufficient to conclude an overall estimation.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

PR Newswire TEL AVIV, Israel, April 17, 2025 Collaboration to Reverse Drug Resistance in GI Cancers TEL AVIV, Israel, April 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (N ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

4 Other frontline options are durvalumab (Imfinzi; AstraZeneca) plus tremelimumab-actl (Imjudo; AstraZeneca) and the single-agent tyrosine kinase inhibitors (TKIs) sorafenib (Nexavar; Bayer ...